Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...

it received a Staff Determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Ma July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 ...

The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 4.9%.

Biodexa Pharmaceuticals has announced that the US FDA has granted Fast Track designation for its drug eRapa, an encapsulated form of rapamycin, which is being developed for familial adenomatous ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

September 26, 2024 Biodexa Pharmaceuticals PLC (Biodexa or the Company) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an ...

it received a Staff Determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Ma July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million ...